Cryoport, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
March 12, 2024 at 04:05 pm EDT
Share
Cryoport, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 57.26 million compared to USD 60.36 million a year ago. Net loss was USD 62.39 million compared to USD 9.44 million a year ago. Basic loss per share from continuing operations was USD 1.31 compared to USD 0.24 a year ago.
For the full year, revenue was USD 233.26 million compared to USD 237.28 million a year ago. Net loss was USD 99.59 million compared to USD 37.33 million a year ago. Basic loss per share from continuing operations was USD 2.21 compared to USD 0.93 a year ago.
Cryoport, Inc. is engaged in supply chain solutions for cell and gene therapies. The Companyâs supply chain solutions enable manufacturers, contract manufacturers (CDMOâs), contract research organizations (CROâs), developers, and researchers to carry out their business with certainty. The Company provides a broad array of supply chain solutions for the life sciences industry. Through its platform of critical products and solutions, including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, the Company is enabling the future of medicine worldwide, through its systems, compliant procedures, and approach to supply chain management. Its products and services include Cryoport Express Shippers, Cryoport ELITE Shipper Systems, Cryoport Consulting Services, Cryoport Bioservices, CRYOGENE, CRYOPDP Temperature-controlled Logistics, Cryoport Cryoshuttle, IntegriCell Services, Tec4Med, and others.
CRYOPORT, INC. 
